Clinical Research Division, Fred Hutch
Dr. Scott Tykodi specializes in translating immunotherapy advances from the laboratory into the clinic. He has led numerous clinical trials evaluating novel, immune-based therapeutics for patients with kidney cancer or other solid tumors. Dr. Tykodi is developing a new cellular immunotherapy for kidney cancer aimed at a marker called 5T4, which is found on the surface of almost all kidney cancer cells and only rarely on healthy adult cells.
For more information, contact:
Ren/Mel Program Coordinator
Associate Professor, Division of Hematology and Oncology
University of Washington School of Medicine
Fellowship: University of Washington Medical Oncology, 2000-2003
Residency: Barnes Hospital Internal Medicine, 1997-2000
Washington University School of Medicine, 1997
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210